Navigation Links
Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2013
Date:2/4/2013

partial response and 91% mean reduction in tumor growth.  In this study, selumetinib resensitized patients to radioactive iodine to warrant further therapy. 

CONFERENCE CALL INFORMATIONArray will hold a conference call on Tuesday, February 5, 2013, at 9:00 a.m. eastern time to discuss these results.  Ron Squarer, Chief Executive Officer, and Michael Carruthers , Chief Financial Officer, will lead the call.Conference Call InformationDate:Tuesday, February 5, 2013Time:9:00 a.m. eastern timeToll-Free:(800) 447-0521Toll:(847) 413-3238Pass Code:34113160Webcast & Conference Call Slides: http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-irhomeAbout Array BioPharma Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company with significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions.  Array-invented MEK162 will begin testing in a Phase 3 trial in NRAS melanoma in April 2013 as well as BRAF mutant melanoma later in the year (with Novartis).  Also, AstraZeneca announced they may start a Phase 3 trial with selumetinib in non-small cell lung cancer during the second half of 2013.  Three other Array invented drugs are also approaching Phase 3 decisions by the end of calendar year 2013. These include Array's wholly-owned drugs, ARRY-520 and ARRY-614, and one partnered program, danoprevir (with InterMune/Roche).  For more information on Array, please go to www.arraybiopharma.com.

Forward-Looking StatementThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform A
'/>"/>

SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology
2. Maine Manufacturing, LLC Announces Global Distribution of FAST® Protein Array Products
3. Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks
4. Phalanx Biotech Group Announces CytoOneArray®, a Targeted Chromosomal Microarray
5. RayBiotech, Inc. and the University of Oslo Enter into Antibody Array Services Collaboration
6. Solar nanowire array may increase percentage of suns frequencies available for energy conversion
7. Array BioPharma to Hold Conference Call on Monday, November 5, 2012 to Discuss Submitted ASH Abstracts
8. Array BioPharma To Present Clinical Data At The 2012 ASH Meeting On ARRY-520, A KSP Inhibitor, And ARRY-614, A Dual p38/Tie2 Inhibitor
9. John A. Orwin Joins Array BioPharma Board Of Directors
10. Array BioPharma Announces Exercise And Closing Of Underwriters Over-Allotment Option
11. Array BioPharma Provides Updates On Clinical Data At The 2012 American Society Of Hematology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Calif. (PRWEB) January 15, 2014 Cynvenio, ... and management through the genomic analysis of tumor cells ... Therapy Finder™, a web-based cancer decision support application powered ... option with Cynvenio’s ClearID™ genomic test, Therapy Finder will ...
(Date:1/15/2014)... More than 5 million Americans are currently living ... will die with Alzheimer’s or another dementia, according to ... many Americans into looking for ways to improve their ... cognitive disorders. Jonathan Weisman, president of Biohack Pure, is ...
(Date:1/15/2014)... 15, 2014 Freeslate, Inc ., ... announced that Lupin Limited, one of India’s top five ... Protégé PharmD System for high throughput solid form ... focused on a wide range of quality, affordable generic ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... Bioactive Small Molecules through ... ... today announced the addition of 1,300 bioactive small molecules to,its ... provides expanded data on the functional relationship between,bioactive small molecules ...
... Enable Healthcare ... Providers Access to PET Technology, HOFFMAN ... today announced its first molecular imaging,biomarker production facility in ... in and around Chennai to access the,positron emission tomography-computed ...
... Burke, MD, Executive Vice,President and Physician-in-Chief at The ... elected the 40th President of the Society of,Gynecologic ... March 9-12, 2008 in Tampa, Florida., Dr. ... Tulane,University in New Orleans, Louisiana. He served both ...
Cached Biology Technology:Sigma-Aldrich Partners With Sunset Molecular Discovery to Expand Your Favorite Gene Search Tool 2Siemens to Launch PETNET Services in India 2Siemens to Launch PETNET Services in India 3Thomas W. Burke, MD, Elected 40th President of the Society of Gynecologic Oncologists 2Thomas W. Burke, MD, Elected 40th President of the Society of Gynecologic Oncologists 3
(Date:4/23/2014)... by a University of Exeter researcher has shed light ... camels thriving in Australia,s remote outback have become reviled ... Sarah Crowley, of the Environment and Sustainability Institute at ... of the camel in Australia, from their historic role ... current status as unwelcome "invader." , The deserts of ...
(Date:4/23/2014)... one can argue that if we were to follow a ... we canthen we can solve the climate problem without doing ... climate researchers, in the current issue of Bulletin of ... significant action on climate change now makes it more likely ... Wigley explains in an exclusive Bulletin interview. ...
(Date:4/22/2014)... 2014 Scientists from the Florida campus of The ... that plays a critical but previously unknown role in ... showed a novel role for a protein known as ... eLife , a publisher supported by the Howard ... Wellcome Trust. , "This is a critical building block ...
Breaking Biology News(10 mins):How Australia got the hump with 1 million feral camels 2How Australia got the hump with 1 million feral camels 3Is nuclear power the only way to avoid geoengineering? 2Scientists identify critical new protein complex involved in learning and memory 2
... 5, 2013 What can the U.S. military learn from ... enemies, according to researchers at UC Irvine,s Henry Samueli School ... in Advanced Materials , they have created a biomimetic ... squids or your everyday calamari. Led by Alon Gorodetsky, ...
... announced today in Milan by the Chairman of the ... President of the Balzan "Prize" Foundation, Ambassador Bruno Bottai, ... profiles of the winners and the citations (the Prizes ... held in Bern on November 15) were presented by ...
... , September 9, 2013 Cytos Biotechnology Ltd ... trial with CYT003, a first-in-class immune modulator in clinical development ... analysis of data published in the March issue of ... presented today at the European Respiratory Society Annual Congress in ...
Cached Biology News:UCI researchers fabricate new camouflage coating from squid protein 22013 Balzan prizewinners announced today in press conference in Milan 22013 Balzan prizewinners announced today in press conference in Milan 3Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma 2Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma 3Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma 4Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma 5
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
PURA Immunogen: PURA (NP_005850, 183 a.a. ~ 293 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to CAMK 1D beta ( Abpromise for all tested applications). entrezGeneID: 57118 SwissProtID: Q5SQQ7...
Acetyl-Histone H2B (Lys20) Antibody...
Biology Products: